Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C7H5O2S.Na |
| Molecular Weight | 176.168 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[O-]C(=O)C1=CC=CC=C1S
InChI
InChIKey=HBAIZOJDXAXWHS-UHFFFAOYSA-M
InChI=1S/C7H6O2S.Na/c8-7(9)5-3-1-2-4-6(5)10;/h1-4,10H,(H,8,9);/q;+1/p-1
| Molecular Formula | C7H5O2S |
| Molecular Weight | 153.178 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Thiosalicylic acid is an analgesic and anti-inflammatory agent. It is used (in form of sodium salt) to relieve symptoms of acute gout, painful musculoskeletal conditions, osteoarthritis and rheumatic fever. The drug exerts its action by inhibiting prostaglandin synthesis. Thiosalicylic acid usage is associated with the risk of contact dermatitis.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | REXOLATE Approved UseTo relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever. |
|||
| Palliative | REXOLATE Approved UseTo relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever. |
|||
| Palliative | REXOLATE Approved UseTo relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever. |
|||
| Primary | REXOLATE Approved UseTo relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Luteolin and thiosalicylate inhibit HgCl(2) and thimerosal-induced VEGF release from human mast cells. | 2011-01-20 |
|
| 14-(1,3-Benzodioxol-5-yl)-7,14-dihydro-dibenzo[a,j]acridine. | 2010-11-06 |
|
| Ultraviolet treatment and biodegradation of dibenzothiophene: Identification and toxicity of products. | 2010-11 |
|
| Low molecular weight thiols reduce thimerosal neurotoxicity in vitro: modulation by proteins. | 2010-10-29 |
|
| Field-assisted synthesis of SERS-active silver nanoparticles using conducting polymers. | 2010-08 |
|
| Intercalation of anionic organic ultraviolet ray absorbers into layered zinc hydroxide nitrate. | 2010-07-01 |
|
| Responsiveness of human monocyte-derived dendritic cells to thimerosal and mercury derivatives. | 2010-07 |
|
| 2-[(2-Carboxy-phen-yl)disulfan-yl]benzoic acid-4,4'-bipyridyl N,N'-dioxide (1/2). | 2010-05-26 |
|
| Sensitization effect of thimerosal is mediated in vitro via reactive oxygen species and calcium signaling. | 2010-03-17 |
|
| Poly[(dimethyl-formamide)(μ(4)-2,2'-sulfanediyldibenzoato)nickel(II)]. | 2010-03-06 |
|
| Electrochemical scanning tunneling spectroscopy of redox-active molecules bound by Au-C bonds. | 2010-03-03 |
|
| Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. | 2010-01 |
|
| Mercury exposure, nutritional deficiencies and metabolic disruptions may affect learning in children. | 2009-10-27 |
|
| Synthesis and characterization of thiosalicylic acid stabilized gold nanoparticles. | 2009-09-15 |
|
| 2-[(2-Carboxy-phen-yl)sulfan-yl]acetic acid. | 2009-09-05 |
|
| The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats. | 2009-07 |
|
| Expression of metallothionein mRNAs on mouse cerebellum microglia cells by thimerosal and its metabolites. | 2009-06-30 |
|
| Ultrasonic-assisted precolumn derivatization-HPLC determination of acrylamide formed in Radix Asparagi during heating process. | 2009-05-01 |
|
| Zinc ions cause the thimerosal-induced signal of fluorescent calcium probes in lymphocytes. | 2009-02 |
|
| [1,2-Bis(diphenyl-phosphino)ethane-κP,P'](2-carboxyl-atothio-phenolato-κO,S)nickel(II) methanol solvate. | 2009-01-08 |
|
| Thimerosal and the relevance of patch-test reactions in children. | 2008-10-11 |
|
| Determination of acrylamide during roasting of coffee. | 2008-08-13 |
|
| Development of a stable isotope dilution assay for the quantitation of glycidamide and its application to foods and model systems. | 2008-08-13 |
|
| Natural products as an inspiration in the diversity-oriented synthesis of bioactive compound libraries. | 2008-08 |
|
| In vitro-refolding of a single-chain Fv fragment in the presence of heteroaromatic thiols. | 2008-04-30 |
|
| Removal of malodorous organic sulfides with molecular oxygen and visible light over metal phthalocyanine. | 2008-03-21 |
|
| Synthesis and biological evaluation of sulfur-containing cinnamate and salicylate derivatives. | 2008-03 |
|
| Cleavage of focal adhesion kinase is an early marker and modulator of oxidative stress-induced apoptosis. | 2008-01-10 |
|
| Competing ligand exchange-solid phase extraction method for the determination of the complexation of dissolved inorganic mercury (II) in natural waters. | 2007-08-29 |
|
| Field amplified sample injection-capillary electrophoresis-tandem mass spectrometry for the analysis of acrylamide in foodstuffs. | 2007-08-03 |
|
| Heterocycles [h]fused onto 4-oxoquinoline-3-carboxylic acid, part IV. Convenient synthesis of substituted hexahydro [1,4]thiazepino[2,3-h]quinoline-9-carboxylic acid and its tetrahydroquino[7,8-b]benzothiazepine homolog. | 2007-07-27 |
|
| Relationship between redox activity and chemical speciation of size-fractionated particulate matter. | 2007-06-07 |
|
| Effect of subinhibitory concentration of some established and experimental antifungal compounds on the germ tube formation in Candida albicans. | 2007 |
|
| Effect of ring substitution position on the structural conformation of mercaptobenzoic acid self-assembled monolayers on Au(111). | 2006-12-19 |
|
| Analysis of acrylamide in food products by in-line preconcentration capillary zone electrophoresis. | 2006-09-29 |
|
| Thimerosal induces apoptosis and G2/M phase arrest in human leukemia cells. | 2006-09 |
|
| Analysis of acrylamide in food samples by capillary zone electrophoresis. | 2006-07-07 |
|
| Uncoupling of ATP-mediated calcium signaling and dysregulated interleukin-6 secretion in dendritic cells by nanomolar thimerosal. | 2006-07 |
|
| Self-assembly of dialkyltin moieties and mercaptobenzoic acid into macrocyclic complexes with hydrophobic "pseudo-cage" or double-cavity structures: supramolecular infrastructures involving intermolecular C-H...S weak hydrogen bonds and pi-pi interactions. | 2005-12-23 |
|
| Determination of mercury complexation in coastal and estuarine waters using competitive ligand exchange method. | 2005-09-01 |
|
| Quantitative description of the deactivation channels of the first excited singlet state of 2- and 4-thiosalicylic acids. | 2005-07-28 |
|
| Chelating sorbents based on silica gel and their application in atomic spectrometry. | 2005-03 |
|
| One-pot synthesis of benzo[e]1,4-oxathiepin-5-ones under solvent-free condition via self-promoted thiolysis of 1,2-epoxides. | 2004-12-10 |
|
| Determination of thiocyl in biological samples by liquid chromatography with ThioGlo 3 derivatization. | 2004-10-05 |
|
| A new positron emission tomography imaging agent for the serotonin transporter: synthesis, pharmacological characterization, and kinetic analysis of [11C]2-[2-(dimethylaminomethyl)phenylthio]-5-fluoromethylphenylamine ([11C]AFM). | 2004-07 |
|
| Using model complexes to augment and advance metalloproteinase inhibitor design. | 2004-05-17 |
|
| Lactic acid triggers, in vitro, thiomersal to degrade protein in the presence of PLGA microspheres. | 2004-04-01 |
|
| Development of a direct-binding chloramphenicol sensor based on thiol or sulfide mediated self-assembled antibody monolayers. | 2004-02-15 |
|
| Preconcentration of lead with Amberlite XAD-2 and Amberlite XAD-7 based chelating resins for its determination by flame atomic absorption spectrometry. | 2002-03-11 |
|
| Cytotoxicity of Triorganophosphinegold(I) n-Mercaptobenzoates, n = 2, 3 and 4. | 2002 |
Sample Use Guides
Acute gout: initial dose is 100 mg every 3 to 4 hours for 2 days, then 100 mg daily. Painful musculoskeletal conditions: 50 to 100 mg daily or every other day. Osteoarthritis: 10 mg 3 times/week for several weeks then once a week, usually up to a total dosage of 2.5 g. Rheumatic fever: initial dose is 100 to 150 mg every 4 to 8 hours for 3 days, then 100 mg two times daily.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:54:02 GMT 2025
by
admin
on
Mon Mar 31 17:54:02 GMT 2025
|
| Record UNII |
C2D9ITW04B
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Mon Mar 31 17:54:02 GMT 2025 , Edited by admin on Mon Mar 31 17:54:02 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
4856
Created by
admin on Mon Mar 31 17:54:02 GMT 2025 , Edited by admin on Mon Mar 31 17:54:02 GMT 2025
|
PRIMARY | |||
|
SUB15331MIG
Created by
admin on Mon Mar 31 17:54:02 GMT 2025 , Edited by admin on Mon Mar 31 17:54:02 GMT 2025
|
PRIMARY | |||
|
C2D9ITW04B
Created by
admin on Mon Mar 31 17:54:02 GMT 2025 , Edited by admin on Mon Mar 31 17:54:02 GMT 2025
|
PRIMARY | |||
|
C87326
Created by
admin on Mon Mar 31 17:54:02 GMT 2025 , Edited by admin on Mon Mar 31 17:54:02 GMT 2025
|
PRIMARY | |||
|
91100
Created by
admin on Mon Mar 31 17:54:02 GMT 2025 , Edited by admin on Mon Mar 31 17:54:02 GMT 2025
|
PRIMARY | RxNorm | ||
|
100000078126
Created by
admin on Mon Mar 31 17:54:02 GMT 2025 , Edited by admin on Mon Mar 31 17:54:02 GMT 2025
|
PRIMARY | |||
|
134-23-6
Created by
admin on Mon Mar 31 17:54:02 GMT 2025 , Edited by admin on Mon Mar 31 17:54:02 GMT 2025
|
PRIMARY | |||
|
23681689
Created by
admin on Mon Mar 31 17:54:02 GMT 2025 , Edited by admin on Mon Mar 31 17:54:02 GMT 2025
|
PRIMARY | |||
|
DTXSID90928380
Created by
admin on Mon Mar 31 17:54:02 GMT 2025 , Edited by admin on Mon Mar 31 17:54:02 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |